<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5131D38B-D801-4D1B-9711-B2EB77E5945A"><gtr:id>5131D38B-D801-4D1B-9711-B2EB77E5945A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL017261%2F1"><gtr:id>6C311109-C9EE-4A80-A497-BE677BD74FBB</gtr:id><gtr:title>Cellular interactions underpinning the anti-inflammatory action of Mesenchymal Stromal Cells in Donation after Cardiac Death liver injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/L017261/1</gtr:grantReference><gtr:abstractText>Chronic liver disease effects approximately 1% of the UK population and is the only cause of death in the top 5 that is still increasing year on year with nearly 12,00 deaths per year due to liver failure. Liver transplantation is the only effective treatment but waiting lists are long, the average time for an adult being 142 days, and a child 78 days. Because of the high demand which cannot currently be met by the number of organs donated, donation after cardiac death (DCD) transplantation is carried out in some centres. The donor liver from these patients has had a much greater insult due to the lack of oxygen following cardiac death as compared to brainstem death. This activates the immune system resulting in damage to the liver, leading to a prolonged ITU stay, and can in cases lead to failure of the new liver. 

Mesenchymal stromal cells (MSC) are powerful cells that have been shown to reduce the damage that the immune system causes, as demonstrated in other conditions such as rheumatoid arthritis and graft versus host disease where the immune system attacks tissues. The purpose of this grant is to demonstrate that MSC are able to reduce damage in models that are similar to DCD liver transplant. 

MSC can home to areas of active inflammation and exert their effect, although recent discoveries indicate that they may be able to exert their effect remotely without migrating to the target organ. Moreover, injection of MSC encapsulated in an alginate coating can prolong the life span and activity of these cells.


My research project will use mouse models of liver injury to test the hypothesis that MSC can be used to reduce the damage seen after DCD liver transplant. I will also look to see if this beneficial effect is affected by how the cells are administered. Specifically I will look to see if MSC encapsulated in special polymers are more effective. This is important as it would suggest they can exert a part of their effect without migrating to the injured liver.

Using state of the art cell tracking technology I will attempt to track the distribution and number of MSC as well as working out where they are exerting their actions. I will achieve the latter by modifying the MSC such that they fluoresce when they are actively reducing inflammation. 

I will then try and establish if MSC are exerting their beneficial effects by acting through an intermediary type of cell in the body (myeloid derived suppressor cells). This might explain how MSC have been act to when they have been encapsulated and not been able to migrate to the injured organ

The knowledge gained during this research will aid the understanding of how MSC exert their effect. It will also determine the most effective route of administration. The possible translation of this into clinical trials would aim to improve the outcomes from DCD transplantation and reduce the risk to the transplant patient.</gtr:abstractText><gtr:technicalSummary>Liver organ shortage has resulted in Donation after Cardiac Death (DCD) transplants with worse outcomes and an acute inflammatory insult causing liver and renal dysfunction with prolonged organ support and intensive care stay. Mesenchymal stromal cells (MSC) suppress immune cells responsible for inflammatory damage and could have a therapeutic role in DCD liver transplant. The optimum route of MSC administration is unclear with subcutaneous injection of alginate encapsulated MSC delivering superior anti-inflammatory action in certain models. I hypothesise that localised subcutaneous injections of encapsulated MSC can provide superior anti-inflammatory action in liver injury, which is mediated through licensing of anti-inflammatory myeloid-derived suppressive (MDSC). 

Aims: (1) To determine impact of route of administration of MSCs in models of immune-mediated liver injury as seen after DCD liver transplantation, (2) determine the functional bio-distribution of infused MSC and (3) determine if MSC exert their action by licensing myeloid derived suppressor cells. 

Methods: I will test the protective action of purified mouse MSC in models of liver injury that replicate the features seen after DCD liver transplant (models of partial hepatic ischaemia:reperfusion &amp;amp; the MDR2-/- model of biliary injury/fibrosis). I will determine whether thermo-reactive encapsulation of MSC provides superior efficacy than conventional routes of administration. To ascertain where MSC are functioning in vivo I will lentivirally transfect MSC with a promoter driven fluorescent protein reporter that reflects indoleamine 2 3- dioxygenase expression. I will determine their bio-distribution using both IVIS &amp;amp; the state of the art CryoVizTM which provides quantitative 3D bio-distribution data in whole mice. Finally, using in vitro then RNA knock-down studies in vivo I will determine whether purified MSC exert their biological effects by induction of myeloid derived suppressor cells.</gtr:technicalSummary><gtr:potentialImpactText>There will be a wide range of beneficiaries from the proposed research due to its wide variety of therapeutic uses.

Impact on commercial private sector beneficiaries
Commercial producers of MSC will benefit from the increased knowledge regarding therapeutic strategies and will enable more direct marketing of cell delivery strategies as well as guiding commercial research endeavours in the field of human stromal cell therapy.

Impact on policy makers and regulators
Novel therapeutic strategies for managing liver transplantation and improving outcomes will enable policy makers to target healthcare research priorities towards funding cellular therapy due to its reduction of critical care bed days and therefore NHS cost reduction.

Impact on People
The project will lead to training of a PhD student who will learn a range of methodologies that are required for the testing of bio-distribution of mesenchymal stromal cells as well as many other laboratory techniques and skills. The research will be embedded in an environment that trains PhD students who contribute to the local and national economies, as well as joining international research groups.

Impact on the Economy
We will continue to contribute to development of the local science infrastructure and in providing skilled researchers needed for academia and industry. The potential impact on health of individuals will have economic benefit.

Impact on public sector beneficiaries
The potential for reducing critical illness and critical care stay will have significant cost and care benefits to the health service. Novel therapeutic strategies for disease management will be of great benefit to the public sector.

Impact on beneficiaries in the wider public
The potential impact on health of individuals will have economic and social benefit.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-08-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-08-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>253403</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Thermoreversible polymer</gtr:description><gtr:id>1C958C72-496D-436D-A681-302E5E507AA7</gtr:id><gtr:impact>Funding application to MRC and Wellcome</gtr:impact><gtr:outcomeId>ZhYN76bgPmK-1</gtr:outcomeId><gtr:partnerContribution>Partner provided thermoreversible polymer for cell encapsulation</gtr:partnerContribution><gtr:piContribution>I provided MSC for use with polymer and have carried out the work for this</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Cancer Sciences</gtr:department><gtr:description>MDSC</gtr:description><gtr:id>2BBF0EE9-6390-4CD3-A38E-3259F08182FA</gtr:id><gtr:impact>Funding application to MRC and Wellcome</gtr:impact><gtr:outcomeId>PcCni29H9mn-1</gtr:outcomeId><gtr:partnerContribution>Partner provided training in se od MDSC</gtr:partnerContribution><gtr:piContribution>I provided MSC and carried out all experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>55931D80-AC34-43F8-A0A9-9CD794567EF5</gtr:id><gtr:title>Structured training in assessment increases confidence amongst basic life support instructors.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922798484ecb6872887279397799360e"><gtr:id>922798484ecb6872887279397799360e</gtr:id><gtr:otherNames>Thorne CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>56a5fbf26870f8.22436602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34687843-B315-4D19-9EFE-F9BF75E281E9</gtr:id><gtr:title>How fast is too fast? Chest compression rate revisited from a new perspective.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d16ccb0cae6058a9f924139edaef28"><gtr:id>d7d16ccb0cae6058a9f924139edaef28</gtr:id><gtr:otherNames>Alderman JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>58c2877ce783d6.71171248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B865DC52-B655-4306-8832-20670DE76684</gtr:id><gtr:title>Use of the learning conversation improves instructor confidence in life support training: An open randomised controlled cross-over trial comparing teaching feedback mechanisms.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a25f2184e2e833d3abaf19664734c36"><gtr:id>9a25f2184e2e833d3abaf19664734c36</gtr:id><gtr:otherNames>Baldwin LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>56a5fbcdee4407.69297875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77603FE1-FF9E-40F3-8890-2558A277BEAE</gtr:id><gtr:title>Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.</gtr:title><gtr:parentPublicationTitle>JAMA internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c30d77f20d29c83f2ed0ec0fa571a8c"><gtr:id>3c30d77f20d29c83f2ed0ec0fa571a8c</gtr:id><gtr:otherNames>Cowley NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-6106</gtr:issn><gtr:outcomeId>5aa6900ee647c4.75741945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECEFD463-8E6B-4C74-BA24-B8180BC67D30</gtr:id><gtr:title>Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5aa6900e90b557.35303090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>033C381E-2F62-4A28-96E7-62EB32276786</gtr:id><gtr:title>A systematic review and meta-analysis of perioperative oral decontamination in patients undergoing major elective surgery.</gtr:title><gtr:parentPublicationTitle>Perioperative medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61d0be3bc5326e0318c9bbbc6bb342c9"><gtr:id>61d0be3bc5326e0318c9bbbc6bb342c9</gtr:id><gtr:otherNames>Spreadborough P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2047-0525</gtr:issn><gtr:outcomeId>58c2877d8afe58.97166133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C19664-E303-4AA4-BD4B-EC7E84E999C8</gtr:id><gtr:title>A novel way to promote mass public engagement in CPR education.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>58c2877d34ea58.96906722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A66361B-AAF1-46F6-8F7F-D94DE1366F48</gtr:id><gtr:title>PURIFIED MESENCHYMAL STROMAL CELLS REDUCE LIVER DAMAGE IN AN ALLO-IMMUNE MODEL OF LIVER DAMAGE (OVA-BIL)</gtr:title><gtr:parentPublicationTitle>JOURNAL OF HEPATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11a0ecf5ba4548e44690dda391218641"><gtr:id>11a0ecf5ba4548e44690dda391218641</gtr:id><gtr:otherNames>Houlihan D. D.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56a5fc4febe505.56489487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A1ABBD1-F0A6-4357-AF2F-8643EFB724A1</gtr:id><gtr:title>Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>56a5fbb438bc63.39290067</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L017261/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>